Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call

Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and
                               Conference Call

PR Newswire

LA JOLLA, Calif., Aug. 6, 2013

LA JOLLA, Calif., Aug. 6, 2013 /PRNewswire/ --Regulus Therapeutics Inc.
(NASDAQ: RGLS), a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, today announced that
it will report financial results and highlights for the quarter ended June 30,
2013 on Tuesday, August 13, 2013, after the U.S. financial markets close.

Regulus will host a conference call and webcast on Tuesday, August 13, 2013 at
5:00 pm Eastern Daylight Time to discuss its second quarter 2013 financial
results and recent company highlights. A live webcast of the call will be
available online at www.regulusrx.com. To access the call, please dial (877)
257-8599 (domestic) or (970) 315-0459 (international) and refer to conference
ID 24265676. To access the telephone replay of the call, dial (855) 859-2056
(domestic) or (404) 537-3406 (international), passcode 24265676. The webcast
and telephone replay will be archived on the company's website following the
call.

About Regulus
Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company
leading the discovery and development of innovative medicines targeting
microRNAs. Regulus is leveraging a mature therapeutic platform based on
technology that has been developed over 20 years. Regulus works with a broad
network of academic collaborators and leverages the oligonucleotide drug
discovery and development expertise of its founding companies, Alnylam
Pharmaceuticals and Isis Pharmaceuticals. Regulus is developing RG-101 for the
treatment of HCV and is advancing other microRNA therapeutics toward clinical
development in several areas, including oncology, fibrosis and metabolic
diseases. Regulus has formed strategic alliances with AstraZeneca,
GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
associated with Regulus' expectations regarding future therapeutic and
commercial potential of Regulus' business plans, technologies and intellectual
property related to microRNA therapeutics being discovered and developed by
Regulus. Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be incorrect. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of various risks
and uncertainties, which include, without limitation, risks associated with
the process of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of building a
business around such drugs. These and other risks concerning Regulus'
programs are described in additional detail in Regulus' SEC filings. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Regulus undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.

SOURCE Regulus Therapeutics Inc.

Website: http://www.regulusrx.com
Contact: Amy Conrad, Director, Investor Relations and Corporate
Communications, Regulus Therapeutics Inc., 858-202-6300,
aconrad@regulusrx.com, or Media, David Schull, Russo Partners LLC,
212-845-4271, david.schull@russopartnersllc.com
 
Press spacebar to pause and continue. Press esc to stop.